Atheroprotective Effects and Molecular Mechanism of Berberine
Lu Xing,Xin Zhou,Ai-Hong Li,Hui-Jin Li,Chun-Xia He,Wei Qin,Dong Zhao,Peng-Quan Li,Li Zhu,Hui-Ling Cao +9 more
12
TL;DR: In this paper, a review highlights the recent advances in understanding the anti-atherosclerosis mechanism of BBR and provides new ideas for atherosclerosis management, including attenuation of dyslipidemia, correction of endothelial dysfunction, inhibition of macrophage inflammation and foam cell formation.
read more
Abstract: Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide. Atherosclerosis is the main pathological basis of cardiovascular diseases and it is closely associated with hyperlipidemia, endothelial injury, macrophage-derived foam cells formation, proliferation and migration of vascular smooth muscle cells (VSMCs), platelet aggregation, and altered gut microbiota. Various symptomatic treatments, that are currently used to inhibit atherosclerosis, need to be administered in long term and their adverse effects cannot be ignored. Berberine (BBR) has beneficial effects on atherosclerosis through regulating multiple aspects of its progression. This review highlights the recent advances in understanding the anti-atherosclerosis mechanism of BBR. BBR alleviated atherosclerosis by attenuation of dyslipidemia, correction of endothelial dysfunction, inhibition of macrophage inflammation and foam cell formation, activation of macrophage autophagy, regulation of the proliferation and migration of VSMCs, attenuation of platelet aggregation, and modulation of gut microbiota. This review would provide a modern scientific perspective to further understanding the molecular mechanism of BBR attenuating atherosclerosis and supply new ideas for atherosclerosis management.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Inhibition of inflammation by berberine: molecular mechanism and network pharmacology analysis
Kaijun Wang,Jie Yin,Jiayi Chen,Jie Ma,Hongbin Si,Diqi Xia +5 more
TL;DR: This study elucidates berberine's anti-inflammatory mechanisms, including inhibition of inflammatory cytokines, NF-κB and MAPK pathways, and enhancement of STAT1 signaling, providing insights into its therapeutic effects against inflammatory diseases through network pharmacology and molecular docking analysis.
37
Berberine Depresses Inflammation and Adjusts Smooth Muscle to Ameliorate Ulcerative Colitis of Cats by Regulating Gut Microbiota
TL;DR: Gut flora analyses were used to demonstrate the anti-UC effects of BBR and its potential therapeutic mechanisms and offers novel insights into the prevention of inflammatory diseases using natural products.
19
Lipid-laden foam cells in the pathology of atherosclerosis: shedding light on new therapeutic targets.
Cristi L Galindo,Yu-Sheng Yeh,Babak Razani +2 more
TL;DR: As key players in atherosclerosis, foam cells are attractive targets for developing more specific, targeted therapies aimed at resolving atherosclerotic plaques.
10
Atherosclerosis: from the disruption of mitochondrial membrane potential to the potential interventional strategies.
TL;DR: In this paper , a review describes how deltapsi contributes to the development of atherosclerosis by mediating oxidative stress, apoptosis, and NLRP3 inflammasome activation.
3
Metformin and the PI3K/AKT signaling pathway: implications for cancer, cardiovascular, and central nervous system diseases
Hemin Ashayeri Ahmadabad,Somayeh Mohammadi Panah,Hojat Ghasemnejad‐Berenji,Shabnam Ghojavand,Morteza Ghasemnejad‐Berenji,Mohammad Rafi Khezri +5 more
2
References
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Emelia J. Benjamin,Paul Muntner,Alvaro Alonso,Márcio Sommer Bittencourt,Clifton W. Callaway,April P. Carson,Alanna M. Chamberlain,Alex R. Chang,Susan Cheng,Sandeep R Das,Francesca N. Delling,Luc Djoussé,Mitchell S.V. Elkind,Jane F. Ferguson,Myriam Fornage,Lori C. Jordan,Sadiya S. Khan,Brett M. Kissela,Kristen L. Knutson,Tak W. Kwan,Daniel T. Lackland,Tené T. Lewis,Judith H. Lichtman,Chris T. Longenecker,Matthew Shane Loop,Pamela L. Lutsey,Seth S. Martin,Kunihiro Matsushita,Andrew E. Moran,Michael E. Mussolino,Martin O'Flaherty,Ambarish Pandey,Amanda M. Perak,Wayne D. Rosamond,Gregory A. Roth,Uchechukwu K.A. Sampson,Gary Satou,Emily B. Schroeder,Svati H. Shah,Nicole L. Spartano,Andrew Stokes,David L. Tirschwell,Connie W. Tsao,Mintu P. Turakhia,Lisa B. VanWagner,John T. Wilkins,Sally S. Wong,Salim S. Virani +47 more
TL;DR: March 5, 2019 e1 WRITING GROUP MEMBERS Emelia J. Virani, MD, PhD, FAHA, Chair Elect On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee.
8.3K
Endothelial Function and Dysfunction Testing and Clinical Relevance
TL;DR: Current understanding of endothelial biology in health and disease, the strengths and weaknesses of current testing strategies, and their potential applications in clinical research and patient care are summarized.
2.7K
Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis
TL;DR: This review traces the evolution of the concept of endothelial cell dysfunction, focusing on recent insights into the cellular and molecular mechanisms that underlie its pivotal roles in atherosclerotic lesion initiation and progression; explores its relationship to classic, as well as more recently defined, clinical risk factors for atherosclerosis.
2.6K
Macrophages in atherosclerosis: a dynamic balance
TL;DR: Recently identified pro- and anti-inflammatory pathways that link lipid and inflammation biology with the retention of macrophages in plaques, as well as factors that have the potential to promote their egress from these sites are summarized.
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).
Alberico L. Catapano,Ian D. Graham,Guy De Backer,Olov Wiklund,M. John Chapman,Heinz Drexel,Arno W. Hoes,Catriona Jennings,Ulf Landmesser,Terje R. Pedersen,Željko Reiner,Gabriele Riccardi,Marja-Riitta Taskinen,Lale Tokgozoglu,W. M. Monique Verschuren,Charalambos Vlachopoulos,David A. Wood,José Luis Zamorano +17 more
TL;DR: Authors/Task Force Members:Alberico L. Catapano (Chairperson) (Italy) , Ian Graham (Chair person) (Ireland) , Guy De Backer (Belgium), Olov Wiklund (Sweden)
1.5K